CIK 0001788028 · <br>Emerging growth company
Jasper Therapeutics, Inc.
Sign in to watch- Ticker
- JSPR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842984849
- Phone
- 6505491400
- Business address
- 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065
- Former names
- Amplitude Healthcare Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-31 | WIGGANS THOMAS G Director | Grant or award · Stock Option (Right to Buy | +7,500 | 7,500 | ||
| 2026-07-31 | Lucas Svetlana Director | Grant or award · Stock Option (Right to Buy | +7,500 | 7,500 | ||
| 2026-07-31 | Crutcher Patrick J Director | Grant or award · Stock Option (Right to Buy | +7,500 | 7,500 | ||
| 2026-07-31 | EMSTER KURT VON Director | Grant or award · Stock Option (Right to Buy | +7,500 | 7,500 | ||
| 2026-07-31 | Shizuru Judith Anne Director | Grant or award · Stock Option (Right to Buy | +7,500 | 7,500 | ||
| 2026-07-20 | Ros Matthew E Chief Operating Officer | Purchase · Non-Voting Convertible Preferred Stock | +881 | 881 | ||
| 2026-07-20 | Crutcher Patrick J Director | Purchase · Non-Voting Convertible Preferred Stock | +888 | 888 | ||
| 2026-07-16 | Crutcher Patrick J Director | Grant or award · Stock Option (Right to Buy | +15,000 | 15,000 | ||
| 2026-02-06 | Mahal Jeetinder Singh CEO and President | Grant or award · Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2026-01-02 | MARTELL RON President, CEO and Director | Grant or award · Stock Option (right to buy) | +234,000 | 234,000 | ||
| 2026-01-02 | Mahal Jeetinder Singh Chief Operating Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2026-01-02 | CROSS HERB Chief Financial Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2025-09-22 | WIGGANS THOMAS G Director | Purchase | +41,000 | $2.43 | $100K | 41,000 |
| 2025-09-22 | WIGGANS THOMAS G Director | Purchase · Common Stock Warrant (right to buy) | +41,000 | 41,000 | ||
| 2025-09-22 | Lucas Svetlana Director | Purchase | +20,000 | $2.43 | $49K | 20,000 |
| 2025-09-22 | Lucas Svetlana Director | Purchase · Common Stock Warrant (right to buy) | +20,000 | 20,000 | ||
| 2025-09-22 | MARTELL RON President and CEO | Purchase | +41,000 | $2.43 | $100K | 74,118 |
| 2025-09-22 | MARTELL RON President and CEO | Purchase · Common Stock Warrant (right to buy) | +41,000 | 41,000 | ||
| 2025-09-22 | Shizuru Judith Anne Director | Purchase | +41,000 | $2.43 | $100K | 156,901 |
| 2025-09-22 | Shizuru Judith Anne Director | Purchase · Common Stock Warrant (right to buy) | +41,000 | 41,000 |
Page 1 of 7 · 129 trades